Browsing Tag
Hikma Pharmaceuticals
8 posts
Hikma Pharmaceuticals commits to $1 billion U.S. generics expansion amid strategic reshoring efforts
Hikma Pharmaceuticals (LSE: HIK) will invest $1B in U.S. manufacturing and R&D to strengthen its position in the generics market and address domestic drug shortages.
Hikma secures exclusive rights to $436M cancer drug in deal with Novugen
Find out how Hikma is strengthening its US oncology portfolio with exclusive rights to a $436M cancer treatment.
Hikma Pharmaceuticals partners with Emergent BioSolutions to expand access to KLOXXADO nasal spray
Hikma Pharmaceuticals PLC has announced an exclusive partnership with Emergent BioSolutions to commercialise KLOXXADO (naloxone HCl) nasal spray…
FDA approves first generic liraglutide injection for Type 2 diabetes treatment
In a significant milestone for diabetes care, the U.S. Food and Drug Administration (FDA) has approved the first…
FDA approval for Zurnai Auto-Injector: A new weapon in the fight against opioid overdose
In a major development in the battle against the opioid epidemic, Purdue Pharma’s Zurnai Auto-Injector has been granted…
Shahin Fesharaki appointed as Lupin Global Chief Scientific Officer
Indian pharmaceutical company Lupin announced that Dr. Shahin Fesharaki has been appointed as Global Chief Scientific Officer who…
Glenmark gets marketing approval for Ryaltris in 13 European countries
Glenmark Pharmaceuticals said that it has secured marketing approval for Ryaltris, a fixed-dose combination nasal spray, in 13…
Bio-Thera, Hikma Pharmaceuticals sign $150m licensing deal for BAT2206
Chinese biopharma company Bio-Thera Solutions has signed a commercialization and license deal worth up to $150 million with…